Spark Therapeutics (NASDAQ:ONCE) was downgraded by equities researchers at Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Thursday. They presently have a $58.00 target price on the biotechnology company’s stock, down from their previous target price of $106.00. Goldman Sachs Group’s price target points to a potential upside of 25.08% from the company’s current price. The analysts noted that the move was a valuation call.

ONCE has been the subject of several other research reports. Jefferies Group reiterated a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, October 10th. SunTrust Banks set a $101.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Monday, October 16th. BMO Capital Markets reissued a “buy” rating and issued a $101.00 target price on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cowen reissued a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Royal Bank of Canada decreased their target price on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the stock. Spark Therapeutics has an average rating of “Buy” and an average target price of $76.19.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $1.16 during trading on Thursday, reaching $46.37. 1,289,066 shares of the company’s stock traded hands, compared to its average volume of 1,417,972. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same quarter last year, the firm earned ($1.07) EPS. Spark Therapeutics’s revenue for the quarter was up 45.8% compared to the same quarter last year. equities analysts expect that Spark Therapeutics will post -7.6 earnings per share for the current fiscal year.

In related news, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the transaction, the chief financial officer now owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the transaction, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The disclosure for this sale can be found here. Insiders sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last 90 days. Corporate insiders own 7.30% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Cornerstone Capital Management Holdings LLC. increased its stake in Spark Therapeutics by 3.2% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 342 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares in the last quarter. Teachers Advisors LLC increased its stake in Spark Therapeutics by 1.9% during the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after purchasing an additional 650 shares in the last quarter. California Public Employees Retirement System increased its stake in Spark Therapeutics by 2.1% during the 2nd quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock valued at $2,336,000 after purchasing an additional 800 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in Spark Therapeutics by 47.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 1,264 shares in the last quarter. Institutional investors and hedge funds own 94.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Spark Therapeutics (ONCE) Stock Rating Lowered by Goldman Sachs Group” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/spark-therapeutics-once-stock-rating-lowered-by-goldman-sachs-group/1768090.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.